Health Economics›Anal cancer›Metastatic disease first-line therapy

Metastatic disease first-line therapy

Anal cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
mDCF Variant #01	—	R 1 957	14d	—	~10.2 mo	~8	~R 15 652 PFS proxy · indirect	1
Cisplatin and Fluorouracil (CF) Variant #01	—	R 1 235	28d	~5.3 mo	~11.5 mo	~7	~R 8 648 PFS proxy · indirect	27
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	7.4 mo	—	9	R 9 222 PFS proxy	1

3 of 3 regimens shown